IDEXX stock traded at $557.90 in an October 16, 2026 market snapshot, up 1.96% for the day but down 3.15% over the preceding three months. The daily advance left the veterinary diagnostics company’s shares below their level three months earlier; the available information does not identify a specific corporate announcement behind the move.
Key Takeaways
- The October 16 snapshot showed a daily gain, not a confirmed closing price.
- Recurring diagnostic tests, laboratory services and software underpin IDEXX’s business.
- Earlier annual results showed earnings growth, partly helped by a litigation-related comparison.
Table of Contents
- IDEXX stock rises within a weaker three-month period
- Recurring testing supports the revenue base
- Earnings growth requires a comparable view
- Conclusion
IDEXX stock rises within a weaker three-month period
The daily and three-month figures describe different trading periods rather than conflicting signals. A positive session can coexist with a decline over a longer window, and neither measure alone establishes a change in operating performance.
The financial results discussed below cover 2025 and were released on February 2, 2026. They provide historical business context, not an explanation for the October 16 share-price movement.
| Item | Details |
|---|---|
| Q4 2025 VetLab consumables | Revenue increased 17% as reported and 15% organically. |
| Q4 2025 reference laboratory services | Revenue increased 11% as reported and 9% organically. |
| Q4 2025 rapid assay products | Revenue declined 2% as reported and 3% organically. |
Recurring testing supports the revenue base
IDEXX supplies veterinary clinics with diagnostic instruments, consumables, infectious-disease tests, reference laboratory services and practice-management software. Instrument placements support subsequent demand for testing supplies, while laboratory services and software add recurring revenue streams.
In its full-year 2025 results announcement, IDEXX reported revenue of $4.304 billion, up 10% both as reported and organically. Companion Animal Group diagnostics recurring revenue increased 9% as reported and 8% organically.
The fourth quarter illustrated how equipment adoption and repeat testing work together. IDEXX placed more than 1,900 inVue Dx instruments, and its global premium instrument installed base expanded 12% year over year. The company also serves water testing and livestock, poultry and dairy markets.
Earnings growth requires a comparable view
Full-year 2025 diluted earnings per share reached $13.08, increasing 23% on a reported basis and 14% on the company’s comparable basis. The reported growth rate included an approximately seven-percentage-point benefit from comparison with the prior year’s discrete litigation expense accrual.
Reported operating margin expanded 270 basis points, including roughly 180 basis points from that litigation-related comparison. Comparable operating margin expanded 90 basis points. The distinction matters because the larger reported improvement was not entirely attributable to underlying operating gains.
Conclusion
The October 16 advance did not erase IDEXX’s three-month decline. In subsequent financial disclosures, recurring diagnostics growth and comparable profitability will be useful measures to track separately from daily share-price changes.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
